In the published article, there was an error in Table 1 as published. The authors found that the occurrence of cephalgia was possibly related the use of nasal spray (Thieme et al., 2020), however, this was omitted in the meta-analysis. The final row of Table 1 (source Thieme et al., 2020) has been corrected to reflect this. The corrected Table 1 and its caption appear below.
TABLE 1.
Basic characteristics of included studies.
| Source | Country | Type of patients | Duration | Intervention | Control Intervention |
Outcomes | Adverse event | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Intervention method (Dose) | Population (Male) |
Mean age | method (Dose) | Population (Male) |
Mean age | ||||||
| Cantone et al., 2016 | Italy | CRSwNP | 3 months | Mometasone furoate nasal spray (200μg, once daily) SH plus saline solution (9mg, twice daily) |
40 | 56.9 ± 5.6α | Mometasone furoate nasal spray (200μg, once daily) Saline solution (5mL, twice daily) |
40 | 56.8 ± 4.4α | Nasal Congestion, Rhinorrhea, Nasal Endoscopy Scoring, Quality of life | No adverse reactions |
| Casale et al., 2014 | Italy | CRS | 3 months | SH plus saline solution (9mg, twice/day) | 21 (13) | 44 (30–63) β | Saline solution (5mL, twice/day) | 18 (10) | 38 (34–58) β | Rhinitis | No adverse reactions |
| Cassandro et al., 2015 | Italy | CRSwNP | 3 months | SH plus saline (9mg, twice daily) | 20 (12) | 38.75 ± 13.08α | Saline (5mL, twice daily) | 20 (11) | 38.6 ± 13.06α | Rhinitis, Mucociliary clearance, Nasal Endoscopy Scoring, Rhinomanometry | Headache, Throat irritation, Upper respiratory infection, Epistaxis, Nasal burning |
| Mometasone furoate nasal sprays (200μg, twice daily) SH (9mg, twice daily) |
20 (12) | 38.85 ± 13.31α | Mometasone furoate nasal sprays (200μg, twice daily) | 20 (10) | 38.4 ± 12.7α | ||||||
| Ciofalo et al., 2017 | Italy | ARS | 30 days | Levofloxacin (500mg, 10days) Prednisone (50mg, 8days; 25mg, 4days; 12.5mg, 4days) SH plus saline solution (6mL, twice daily) |
24 (12) | 44 (38–50) * | Levofloxacin (500mg, 10days) Prednisone (50mg, 8days; 25mg, 4days; 12.5mg, 4days) Saline solution (6mL, twice daily) |
24 (14) | 43 (35–55) * | Nasal Congestion, Rhinorrhea, Eosinophils, Neutrophils, mucociliary clearance, Hyposmia | Not reported |
| Ercan et al., 2022 | Turkey | AR in children | 28 days | Nasal fluticasone furoate (1 puff/nostril, once daily) SH (twice daily) |
26 (18) | 8.38 ± 1.89α | Nasal fluticasone furoate (1 puff/nostril, once daily) Saline solution (twice daily) |
24 (12) | 8.5 ± 1.31α | Nasal Congestion, Rhinorrhea, Rhinitis, Itching, Sneezing, Eosinophils, Quality of life, Rhinomanometry | Nasal irritation and burning sensation |
| Nasal fluticasone furoate (1 puff/nostril, once daily) SH (twice daily) |
26 (18) | 8.38 ± 1.89α | Nasal fluticasone furoate (1 puff/nostril, once daily) | 26 (18) | 8.69 ± 1.7α | ||||||
| Favilli et al., 2019 | Italy | Pregnancy Rhinitis | until delivery | SH (9mg/vial; 2 vials daily for 14 days, followed by 15 days of interruption of therapy; subsequently 1 vial daily for 10 and 15 days of interruption of therapy; lastly 1 vial daily for 10 days) | 28 | 31.6 ± 5.5α | Not receive any treatment | 27 | 28.1 ± 4.8α | Rhinorrhea | No adverse reactions |
| Gelardi et al., 2013 | Italy | AR and vasomotor rhinitis | 30 days | Mometasone furoate nasal spray (50μg/spray, 2 sprays/nostril once daily) Desloratadine (5mg, once daily) SH (9mg, twice daily) |
39 (23) | 21–63β | Mometasone furoate nasal spray (50μg/spray, 2 sprays/nostril once daily) Desloratadine (5mg, once daily) Sodium chloride (6mL, twice daily) |
39 (21) | 22–61β | Nasal Congestion, Rhinorrhea, Eosinophils, Neutrophils | Not reported |
| Gelardi et al., 2016 | Italy | AR, NAR, and MR | 4 weeks | intranasal mometasone furoate (1 puff/nostril, twice daily) rupatadine fumarate (1 tablet daily) isotonic saline solution (1 puff/nostril, twice daily) SH (1 cm per nostril in the afternoon) |
48 | Not reported | intranasal mometasone furoate (1 puff/nostril, twice daily) rupatadine fumarate (1 tablet daily) isotonic saline solution (1 puff/nostril, twice daily) |
41 | Not reported | Nasal Congestion, Rhinorrhea, Itching, Sneezing, Hyposmia | No adverse reactions |
| Ocak et al., 2021 | Turkey | AR | 30 days | Triamcinolone acetonide sprays (256 μg/day, 1 puff/nostril, once daily) Desloratadine (5mg, once daily) SH (9mg, twice daily) |
32 (14) | 34 (18–68) β | Triamcinolone acetonide sprays (256 μg daily, 1 puff/nostril, once daily) Desloratadine (5mg, once daily) Isotonic saline (9mg, twice daily) |
33 (13) | 36 (18–61) β | Mucociliary clearance | No adverse reactions |
| Savietto et al., 2020 | Italy | CRSsNP | 30 days | SH (5mg, twice daily) | 15 | Not reported | Isotonic saline solution (5mg, twice daily) | 15 | Not reported | Nasal Congestion, Rhinorrhea, Eosinophils, Neutrophils, Nasal Endoscopy Scoring, Quality of life, Hyposmia | No adverse reactions |
| Thieme et al., 2020 | Germany | Dry nose symptoms | 4 weeks | SH (1–2 sprays/nostril)/Hyaluronic acid plus dexpanthenol (1–2 sprays/nostril) | 79 (41)/ 80 (25) |
54.15 ± 17.03α/50.60 ± 18.98α | Isotonic saline (1–2 sprays/nostril) | 80 (31) |
50.27 ± 19.7α | Nasal Congestion, Rhinorrhea, Rhinitis, Itching, Sneezing, Hyposmia | Cephalgia |
CRS, chronic rhinosinusitis; CRSwNP, chronic rhinosinusitis with nasal polyposis; CRSsNP, chronic rhinosinusitis without nasal polyposis; ARS, acute rhinosinusitis; NAR, nonallergic rhinitis; MR: mixed rhinitis; SH, sodium hyaluronate; α, Mean age ± SD; β, Mean age (range); *, median (IQR).
In the published article, there was an error. The authors found that the occurrence of cephalgia was possibly related the use of nasal spray (Thieme et al., 2020), however, this was omitted in the meta-analysis.
A correction has been made to 3 Results, 3.4 Outcomes, 3.4.4 Adverse events, Paragraph Number 1. The sentences previously stated:
“These studies (Cassandro et al., 2015; Ercan et al., 2022) reporting adverse events included nasal burning, headaches, throat irritation, upper respiratory tract infections, epistaxis, and nasal irritation. One trial (Cassandro et al., 2015) reported no difference in the incidence of adverse events between the HA and control groups, and the other trial (Ercan et al., 2022) showed only mild adverse events in the control group.”
The corrected sentence appears below:
“These studies (Cassandro et al., 2015; Ercan et al., 2022) reported adverse events including nasal burning, headache, throat irritation, upper respiratory tract infection, epistaxis, and nasal irritation. One patient reported thrice about the occurrence of cephalgia in hyaluronic acid plus dexpanthenol group, rated as possibly related to the application of the nasal spray (Thieme et al., 2020). One trial (Cassandro et al., 2015) reported no difference in the incidence of adverse events between the HA and control groups, and the other trial (Ercan et al., 2022) showed only mild adverse events in the control group.”
In the published article, there was an error in Table 1. In the final row, “α” was not in superscript. The corrected table and its caption appear above.
The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.